



67 children are severely wasted (weight-for-height/length  $\leq 3$   
68 SD). Since “wasting” denotes acute malnutrition, these  
69 children are said to have SAM [7].

70 Treatment of children with SAM is divided into three  
71 phases: stabilization, transition, and rehabilitation. The  
72 goal is first to stabilize, treat life-threatening complica-  
73 tions, and then to feed the child intensively to allow for  
74 catch-up growth [8,9]. Deficiencies of phosphorus, potas-  
75 sium, calcium, and other minerals are common in children  
76 with SAM. While treating these deficiencies, refeeding  
77 with diets high in carbohydrate can result in refeeding  
78 syndrome, characterized by hypophosphatemia and hypo-  
79 magnesemia, sometimes resulting in respiratory or cir-  
80 culatory failure or even death. Although concentrations  
81 of serum phosphate and magnesium may not adequately  
82 reflect body status, low levels may still be suggestive of  
83 inadequate intake [9].

84 In starvation, the secretion of insulin is decreased in  
85 response to a reduced intake of carbohydrates. Instead,  
86 fat and protein stores are catabolized to produce energy.  
87 This results in an intracellular loss of electrolytes, in par-  
88 ticular phosphate. When feeding is started (usually on day  
89 4), a sudden shift from fat to carbohydrate metabolism  
90 occurs, and secretion of insulin increases. This stimulates  
91 cellular uptake of phosphate, which can lead to profound  
92 hypophosphatemia. Serum phosphate concentrations of  
93 less than 3.7 mg/dl can produce the clinical features of  
94 refeeding syndrome, including rhabdomyolysis, leukocyte  
95 dysfunction, respiratory failure, cardiac failure, hypoten-  
96 sion, arrhythmias, seizures, coma, and sometimes sudden  
97 death [10].

98 Overall, India has the highest prevalence of SAM as  
99 per NFHS-5 [7], with a higher burden of SAM in the  
100 study area. SAM is a clinical syndrome due to an imbal-  
101 ance between the demand and supply of energy content,  
102 proteins, and micronutrients, with a complex interplay of  
103 various pathological mechanisms. Children with SAM  
104 have increased total body water and sodium, while there  
105 is a deficiency of potassium, magnesium, and phosphate  
106 stores [11].

107 As per WHO guidelines, SAM children are treated with  
108 a starter F-75 diet (containing 75 calories) initially for 3  
109 to 7 days and later with a catch-up F-100 diet (contain-  
110 ing 100 calories) from locally available ingredients con-  
111 taining 300 and 900 ml of skimmed milk per 1,000 ml of  
112 F-75 and F-100 diets, respectively. During refeeding due  
113 to anabolism and insulin release, increased cellular uptake  
114 of electrolytes like phosphorus, potassium, and magne-  
115 sium occurs. This leads to hypophosphatemia, hypokal-  
116 aemia, and hypomagnesemia with resultant increased  
117 mortality and morbidity. Clinical features of these bio-  
118 chemical changes are non-specific and may be misin-  
119 terpreted as sepsis. Serum electrolytes are not routinely  
120 monitored; hence, adequate content of these micronutri-  
121 ents in the diet is essential to prevent depletion. Potassium

and magnesium supplements are routinely supplemented, 122  
while diet is the main source for phosphorus [12,13]. 123

124 However, locally prepared starter diet may have limited  
125 amounts of phosphorus during stabilization as compared  
126 to 60 mg/kg/day recommended by WHO, and is likely to  
127 be less effective in normalizing phosphate levels, leading  
128 to adverse outcomes like increasing mortality, inadequate  
129 weight gain, prolongation of hospital stay, and other long-  
130 term morbidities [14]. The present study was planned to  
131 determine the serum phosphate profile in children admit-  
132 ted with SAM through the identification of changes in  
133 serum phosphorus levels, incidence of hypophosphatemia,  
134 and differences in the clinical profile.

## 135 Subjects and Methods

136 This hospital-based prospective observational study was  
137 conducted over 12 months from January to December  
138 2024 in the Department of Paediatrics at a tertiary-care  
139 teaching hospital in New Delhi, India. Ethical approval  
140 was obtained from the Institutional Ethics Committee  
141 before study initiation.

142 Sample size was calculated using the formula for  
143 paired mean difference:  $n = (Z\alpha/2 + Z1-\beta)^2 \times SD^2 / d^2$ ,  
144 where  $Z\alpha/2 = 1.96$  ( $\alpha = 0.05$ , 95% CI),  $Z1-\beta = 1.28$  (power  
145 90%),  $SD = 0.2$  mg/dl (expected standard deviation of  
146 change in serum phosphate from admission to end of sta-  
147 bilization phase), and  $d = 0.1$  mg/dl (clinically meaningful  
148 difference). This yielded a minimum required sample of  
149 42 participants. Anticipating a 20% attrition/drop-out rate,  
150 the target sample size was increased to 53. Ultimately, 60  
151 children who met the eligibility criteria were enrolled.

152 Children aged 6-59 months admitted with SAM along  
153 with an acute medical illness were eligible. SAM was  
154 diagnosed according to WHO/UNICEF criteria: weight-  
155 for-height/length  $\leq$ SD of WHO growth standards, MUAC  
156  $< 11.5$  cm, or bilateral nutritional pitting oedema [4,5].  
157 Children with known chronic illnesses (congenital mal-  
158 formations, rickets, chronic kidney disease, endocrine  
159 disorders, malabsorption syndromes, tuberculosis, or  
160 HIV) were excluded. After screening, parents or legal  
161 guardians of eligible children were provided with detailed  
162 information about the study in their preferred language.  
163 Written informed consent was obtained before enrol-  
164 ment. A structured, pretested proforma was used to record  
165 demographic details (age, sex, socioeconomic status using  
166 Modified B.G. Prasad Classification 2024 update [18]),  
167 dietary history, immunization status, and clinical findings.  
168 Anthropometric measurements (weight, length/height,  
169 MUAC) were performed by trained staff using stand-  
170 arized techniques and equipment calibrated daily. All  
171 children were managed as per the WHO 2013 guidelines  
172 for inpatient treatment of complicated SAM [8,9]. Initial  
173 stabilization was carried out using a locally prepared  
174 F-75 formula, followed by transition to F-100 during the  
175 rehabilitation phase. Routine potassium and magnesium

176 supplementation was provided; additional electrolyte cor-  
177 rection was performed when clinically indicated.

178 Laboratory investigations Venous blood samples (1  
179 ml each) were collected under strict aseptic precautions  
180 in plain vacutainers at three time points: 1) At admis-  
181 sion (before initiation of therapeutic feeding), 2) On day  
182 4 ( $\pm$ 12 hours) of the stabilization phase, 3) At discharge  
183 (only in children with hypophosphataemia on day 4). An  
184 additional 2-ml blood sample in an Ethylene-diamine-  
185 tetraacetic acid vacutainer was collected at admission  
186 for complete blood count. Serum inorganic phosphate,  
187 potassium, sodium, and total calcium were estimated by  
188 an automated analyzer (cobas integra 400 plus/equivalent)  
189 using standard reagents. Hypophosphataemia was defined  
190 using age-specific reference ranges: 6-36 months: serum  
191 phosphate < 3.8 mg/dl, 37-60 months: serum phosphate <  
192 3.7 mg/dl. Anemia was defined as hemoglobin < 11 g/dl,  
193 and sepsis as systemic inflammatory response syndrome  
194 with suspected or proven infection.

### 195 **Statistical analysis**

196 Data were entered into Microsoft Excel and analyzed  
197 using IBM SPSS version 26.0. Categorical variables are  
198 presented as frequencies and percentages; continuous  
199 variables as mean  $\pm$  SD or median interquartile ranges

(IQR), depending on distribution. Sample size estima- 200  
tion was performed using the paired mean difference 201  
approach based on anticipated changes in serum phos- 202  
phate from admission to stabilization, as distribution 203  
characteristics were not known during study planning. 204  
Normality was assessed using the Kolmogorov-Smirnov 205  
test. As the collected data demonstrated non-normal 206  
distribution, non-parametric methods were used where 207  
appropriate. Paired changes in serum phosphate and 208  
weight were analyzed using a paired *t*-test (normally 209  
distributed data) or Wilcoxon signed-rank test (non-nor- 210  
mal data). Between-group comparisons were performed 211  
using an independent *t*-test/Mann-Whitney *U* test or  $\chi^2$ / 212  
Fisher's exact test as appropriate. A two-tailed *p*-value 213  
 $\leq 0.05$  was considered statistically significant. 214

### 215 **Results**

216 A total of 60 children with complicated SAM were  
217 enrolled.

218 All continuous variables demonstrated non-normal  
219 distribution on Kolmogorov-Smirnov testing; therefore,  
220 medians with IQR were used for descriptive purposes, and  
221 non-parametric tests were applied for comparisons.

222 The baseline characteristics of the study population  
223 are presented in Table 1. The cohort comprised 27 boys

**Table 1.** Distribution of children according to demographic and clinical characteristics and their association with serum phosphorus status.

Parameter	Subgroup	Normal phosphorous (n = 37) No. (%)	Low phosphorous (n = 23) No. (%)	Total (n = 60) No. (%)	p value
Age group (months)	6-12	13 (56.52)	10 (43.48)	23 (38.33)	0.846
	13-24	12 (63.16)	7 (36.84)	19 (31.67)	
	25-36	2 (50.00)	2 (50.00)	4 (6.67)	
	37-48	3 (60.00)	2 (40.00)	5 (8.33)	
	49-60	7 (77.78)	2 (22.22)	9 (15.00)	
Sex	Boys	19 (70.37)	8 (29.63)	27 (45.00)	0.287
	Girls	18 (54.55)	15 (45.45)	33 (55.00)	
Socio-economic class	Class 3	8 (66.67)	4 (33.33)	12 (20.00)	0.215
	Class 4	22 (55.00)	18 (45.00)	40 (66.67)	
	Class 5	7 (87.50)	1 (12.50)	8 (13.33)	
Clinical profile	Immunization up-to-date	28 (60.87)	18 (39.13)	46 (76.67)	1
	Exclusive breastfeeding ( $\leq 6$ mo)	15 (65.22)	8 (34.78)	23 (38.33)	0.787
	Acute gastroenteritis	13 (68.42)	6 (31.58)	19 (31.67)	0.573
	Sepsis	6 (46.15)	7 (53.85)	13 (21.67)	0.164
	Fever	5 (71.43)	2 (28.57)	7 (11.67)	0.451
	Lethargy/excessive sleepiness	4 (57.14)	3 (42.86)	7 (11.67)	0.549
	Abdominal distension	5 (83.33)	1 (16.67)	6 (10.00)	0.247
SAM criteria	Convulsions	2 (100.00)	0 (0.00)	2 (3.33)	0.376
	Weight-for-height/length	33 (58.93)	23 (41.07)	56 (93.33)	0.135
	MUAC <11.5 cm	33 (61.11)	21 (38.89)	54 (90.00)	0.58
	Bilateral pedal oedema	6 (54.55)	5 (45.45)	11 (18.33)	0.417

Parameter	Subgroup	Normal phosphorous (n = 37) No. (%)	Low phosphorous (n = 23) No. (%)	Total (n = 60) No. (%)	p value
Hemoglobin (g/dl)	<11	29 (58.00)	21 (42.00)	50 (83.33)	0.172
	≥11	8 (80.00)	2 (20.00)	10 (16.67)	
Serum sodium (mEq/l)	<135	9 (45.00)	11 (55.00)	20 (33.33)	0.13
	135-145	22 (66.67)	11 (33.33)	33 (55.00)	
	>145	6 (85.71)	1 (14.29)	7 (11.67)	
Serum potassium (mEq/l)	<3.5	6 (35.29)	11 (64.71)	17 (28.33)	0.019
	3.5-6.0	29 (70.73)	12 (29.27)	41 (68.34)	
	>6.0	2 (100.00)	0 (0.00)	2 (3.33)	
Serum calcium (mmol/l)	<2.1	2 (16.67)	10 (83.33)	12 (20.00)	0.001
	2.1-2.75	33 (71.74)	13 (28.26)	46 (76.67)	
	>2.75	2 (100.00)	0 (0.00)	2 (3.33)	

**Table 2.** Comparison of children according to the serum phosphorus levels at admission, on day 4, and discharge.

Time interval	Normal serum phosphorous No. (%)	Low serum phosphorous No. (%)
Admission	37 (61.67)	23 (38.33)
Day 4	52 (86.67)	8 (13.33)
Discharge	60 (100.00)	0 (0.00)

224 and 33 girls (male:female ratio 1:1.22). The median age  
 225 was 18 months (IQR 12-30). Hypophosphataemia (using  
 226 age-specific cut-offs) at any point during hospitalization  
 227 was observed in 23 children (38.3%). No significant  
 228 associations were found between hypophosphataemia  
 229 and sex, age group, socioeconomic status, type of SAM  
 230 (oedematous vs. non-oedematous), presence of anemia, or  
 231 admission diagnosis (all  $p > 0.05$ ). Hyponatraemia (< 135  
 232 mEq/l) was present in 20 children (33.3%) and hypokalaemia  
 233 (< 3.5 mEq/l) in 17 children (28.3%). Both hyponatraemia  
 234 and hypokalaemia were significantly associated  
 235 with hypophosphataemia ( $p < 0.05$  for both; Table 1).

236 Serial serum inorganic phosphate levels are summarized  
 237 in Table 2. At admission, 23 children (38.3%) had  
 238 hypophosphataemia. On day 4 of the stabilization phase,  
 239 the prevalence decreased to 8 children (13.3%). Serum  
 240 phosphate was re-measured at discharge only in those  
 241 eight children who had hypophosphataemia on day 4; all  
 242 had normalized by discharge (0% hypophosphataemia  
 243 among re-tested children). The decrease in prevalence  
 244 from admission to day 4 (among the full cohort of 60) was  
 245 statistically significant ( $p < 0.001$ , McNemar test).

246 Clinical and biochemical parameters at admission,  
 247 stratified by serum phosphate status at admission (normal  
 248 vs. hypophosphataemia), are compared in Table 3.  
 249 Children with hypophosphataemia at admission exhibited  
 250 significantly higher median respiratory rate (32 vs. 28  
 251 breaths/min,  $p = 0.021$ ), lower median serum sodium (135

vs. 137 mEq/l,  $p = 0.027$ ), lower serum potassium (3.6  
 252 vs. 3.8 mEq/l,  $p = 0.003$ ), and lower serum calcium (2.1  
 253 vs. 2.4 mmol/l,  $p < 0.001$ ). As expected, median serum  
 254 phosphate at admission (3.5 vs. 3.9 mg/dl,  $p < 0.001$ ) and  
 255 on day 4 (3.8 vs. 5.0 mg/dl,  $p < 0.001$ ) was significantly  
 256 lower in the hypophosphataemia group. No significant  
 257 differences were observed in age, anthropometric meas-  
 258 urements, heart rate, temperature, hemoglobin, leukocyte  
 259 counts, differential counts, platelet count, or weight gain  
 260 during hospitalization.  
 261

## 262 Discussion

263 SAM remains a life-threatening condition, and refeeding  
 264 hypophosphataemia is increasingly recognized as a key  
 265 contributor to early mortality during inpatient manage-  
 266 ment. This prospective study of 60 children with com-  
 267 plicated SAM provides detailed insights into the natural  
 268 history of serum phosphate during standardized WHO-  
 269 protocol treatment using locally prepared therapeutic  
 270 feeds.

271 At admission, the median serum inorganic phosphate  
 272 was 3.81 mg/dl (IQR 0.20), with a range of 2.2 0-5.20  
 273 mg/dl. These values are comparable to those reported by  
 274 Yoshimatsu et al. [13] (Japan, 2013), Selvaraj et al. [15]  
 275 (India, 2021), and Dakshayani et al. [14] (India, 2019),  
 276 but higher than those documented by Namusoke et al.  
 277 [11] (Uganda, 2016), Chanchal et al. [12] (India, 2019),  
 278 and Khan et al. [16] (India, 2023). The observed differ-  
 279 ences likely reflect variations in the duration of preceding  
 280 starvation, severity of illness, and preadmission dietary  
 281 intake.

282 Hypophosphataemia (using age-adjusted cut-offs) was  
 283 present in 38.3% of children at admission and decreased  
 284 significantly to 13.3% on day 4 of the stabilization phase  
 285 ( $p < 0.001$ ). Serum phosphate normalized in all retested  
 286 children (those with hypophosphataemia on day 4) by  
 287 discharge. This pattern contrasts with the expected rise in

**Table 3.** Comparison of mean serum levels and mean weight at admission and discharge.

Parameter	Normal phosphorous (n = 37) Median (IQR)	Low phosphorous (n = 23) Median (IQR)	p value
Age (months)	15.00 (28.00)	13.00 (14.00)	0.615
Weight at admission (kg)	6.80 (4.55)	6.50 (3.00)	0.538
Length/Height (cm)	75.80 (26.00)	73.50 (16.50)	0.533
MUAC (cm)	11.20 (0.40)	11.40 (0.50)	0.202
Heart rate (per minute)	96.00 (22.00)	98.00 (20.00)	0.074
Respiratory rate (per minute)	28.00 (8.00)	32.00 (12.00)	0.021
Temperature (°F)	100.80 (3.30)	101.20 (2.80)	0.137
Hemoglobin (g/dl)	9.00 (3.80)	8.40 (3.00)	0.563
Total leukocyte count (per cumm)	12,000 (8,250)	9,800 (7,600)	0.605
Neutrophils (%)	60.00 (27.00)	55.00 (32.00)	0.853
Lymphocytes (%)	35.00 (26.00)	35.00 (26.00)	0.889
Eosinophils (%)	2.00 (2.00)	2.00 (2.00)	0.24
Monocytes (%)	4.00 (3.00)	4.00 (3.00)	0.769
Platelet count (per cumm)	238,000 (218,000)	204,000 (317,000)	0.865
Serum sodium (mEq/l)	137.00 (6.50)	135.00 (9.00)	0.027
Serum potassium (mEq/l)	3.80 (0.70)	3.60 (0.80)	0.003
Serum calcium (mmol/l)	2.40 (0.20)	2.10 (0.30)	<0.001
Serum phosphorous at admission (mg/dl)	3.90 (0.17)	3.50 (0.92)	<0.001
Serum phosphorous on Day 4 (mg/dl)	5.00 (0.65)	3.80 (0.80)	<0.001
Weight at discharge (kg)	6.70 (4.47)	6.82 (2.95)	0.494
Weight gain (kg)	0.10 (0.17)	0.08 (0.08)	0.225

288 hypophosphataemia during early refeeding due to insu-  
 289 lin-driven cellular phosphate uptake, suggesting that the  
 290 locally prepared F-75 formula provided sufficient phos-  
 291 phorus to prevent worsening or to facilitate early correc-  
 292 tion in most cases. The admission prevalence of 38.3%  
 293 reported here aligns closely with Namusoke et al. [11]  
 294 (38%) but is higher than the 20%-25% noted by Selvaraj  
 295 et al. [15] and Dakshayani et al. [14] and lower than the  
 296 50%-69% described in some other cohorts [16-18]. The  
 297 lower prevalence on day 4 compared to admission may  
 298 reflect differences in the phosphorus content of therapeutic  
 299 feeds, timing of sampling relative to refeeding initiation,  
 300 baseline nutritional status, or the severity of concurrent  
 301 illnesses such as sepsis or dehydration.

302 We observed no significant association between  
 303 hypophosphataemia and sex, age group, socioeconomic  
 304 class (Modified B.G. Prasad), type of SAM (oedematous  
 305 vs. non-oedematous), anaemia, or admission clinical diag-  
 306 nosis. This independence from demographic and anthro-  
 307 pometric factors has been a consistent finding across  
 308 Indian studies [14,15].

309 A clinically important observation was the association of  
 310 hypophosphataemia with concurrent electrolyte abnormal-  
 311 ities. Children with hypophosphataemia had significantly  
 312 lower serum sodium, potassium, and calcium levels com-  
 313 pared with children with normal phosphate levels. Similar  
 314 associations have been reported previously and highlight

the need for comprehensive electrolyte monitoring during 315  
 stabilization and refeeding in children with SAM. 316

317 Among children who remained hypophosphataemic on  
 318 Day 4 and underwent repeat testing at discharge, serum  
 319 phosphate levels had normalized by discharge. Although  
 320 these findings suggest recovery of phosphate status during  
 321 treatment, phosphate levels at discharge were not measured  
 322 in the entire cohort, and therefore, conclusions regarding  
 323 normalization cannot be generalized to all participants.  
 324 Weight gain during hospitalization was comparable  
 325 between children with and without hypophosphataemia.  
 326 This finding suggests that the presence of hypophospha-  
 327 taemia during stabilization did not significantly influence  
 328 short-term nutritional recovery in this cohort.

329 Strengths of this study include prospective data col-  
 330 lection, serial assessment of serum phosphate at clini-  
 331 cally relevant time points, use of age-specific reference  
 332 ranges, and standardized management according to WHO  
 333 guidelines.

334 The study has several limitations. It was conducted at  
 335 a single tertiary-care centre with a relatively small sample  
 336 size, which may limit generalizability. The phosphorus  
 337 content of the locally prepared F-75 and F-100 feeds was  
 338 not directly measured; therefore, conclusions regarding  
 339 adequacy of phosphorus provision are based on observed  
 340 biochemical trends rather than quantified dietary phospho-  
 341 rus intake. Important clinical outcomes such as duration

342 of hospital stay, mortality, complications attributable  
343 to refeeding syndrome, and requirement for additional  
344 electrolyte correction were not systematically evaluated.  
345 Serum magnesium and thiamine levels were not routinely  
346 measured, limiting assessment of other important compo-  
347 nents of refeeding syndrome. In addition, post-discharge  
348 follow-up was not performed.

### 349 Conclusion

350 Hypophosphataemia affected more than one-third of  
351 children with complicated SAM and was associated with  
352 concurrent abnormalities of sodium, potassium, and cal-  
353 cium. The prevalence of hypophosphataemia decreased  
354 significantly during the stabilization phase of treatment.  
355 Among children who remained hypophosphataemic on  
356 Day 4 and underwent repeat testing, serum phosphate  
357 levels had normalized by discharge. These findings sup-  
358 port the importance of careful electrolyte monitoring  
359 during refeeding and highlight the need for larger multi-  
360 centre studies to better define phosphate requirements in  
361 children with SAM.

### 362 What is new?

363 This study provides prospective data on serum phosphate  
364 changes during inpatient management of SAM in Indian  
365 children. Hypophosphataemia was common at admission  
366 and decreased significantly during the stabilization phase.  
367 Children with hypophosphataemia had more frequent con-  
368 current electrolyte abnormalities involving sodium, potas-  
369 sium, and calcium. The study also demonstrates improvement  
370 in serum phosphate levels during treatment with locally pre-  
371 pared WHO-recommended therapeutic feeds.

### 372 Acknowledgment

373 None.

### 374 List of Abbreviations

375	CBC	Complete blood count
376	F-75	Starter therapeutic diet (75 kcal/100 ml)
377	F-100	Catch-up therapeutic diet (100 kcal/100 ml)
378	IQR	Interquartile range
379	MUAC	Mid-upper arm circumference
380	NFHS	National family health survey
381	SAM	Severe acute malnutrition
382	SD	Standard deviation
383	SPSS	Statistical Package for the Social Sciences
384	UNICEF	United Nations Children's Fund
385	WHO	World Health Organization

### 386 Conflict of interests

387 The authors declare that there is no conflict of interest regard-  
388 ing the publication of this article.

### 389 Funding

390 None.

### 391 Consent to participate

392 Written informed consent was obtained from the parents/legal  
393 guardians of all participants before enrolment.

### Ethical approval

394 Example for original (Research) articles: Ethical approval was  
395 granted by the Ethics Committee/Institutional Review Board/  
396 Research Committee via reference/letter number- 27924403  
397 dated: 19th October 2022. 398

### Author details

399 Pooja Gautam<sup>1</sup>, Deepak Gupta<sup>2</sup>, Rohan Acharya<sup>3</sup>, Kanika  
400 Agarwal<sup>4</sup>, Ankush Gautam<sup>5</sup> 401  
402 1. Senior Resident, Department of Paediatrics, Sanjay Gandhi  
403 Memorial Hospital, New Delhi, India 404  
405 2. Professor, Department of Paediatrics, Sanjay Gandhi  
406 Memorial Hospital, New Delhi, India 407  
408 3. Senior Resident, Department of Paediatric Cardiology, Sri  
409 Jayadeva Institute of Cardiovascular Sciences and Research,  
410 Bengaluru, India 411  
412 4. Senior Resident, Department of Anaesthesia and Intensive  
413 Care, Vardhman Mahavir Medical College, Safdarjung  
414 Hospital, New Delhi, India 415

### References

1. Kleigman RM, St Geme JW, Blum NJ, Tasker RC, Wilson  
416 KM, Schuh AM. Nelson textbook of pediatrics. Elsevier;  
417 2022. 418
2. World Health Organization. Child development. Geneva,  
419 Switzerland: World Health Organization [cited 2025  
420 Dec 11]. Available from: [https://www.who.int/topics/  
421 child\\_development/en](https://www.who.int/topics/child_development/en) 422
3. World Health Organization. Malnutrition. Geneva,  
423 Switzerland: World Health Organization [cited 2025 Dec  
424 11]. Available from: [https://www.who.int/newsroom/  
425 fact-sheets/detail/malnutrition](https://www.who.int/newsroom/fact-sheets/detail/malnutrition) 426
4. World Health Organization. Geneva, Switzerland:  
427 World Health Organization [cited 2025 Dec 11].  
428 Available from: [https://www.who.int/news-room/  
429 questionsand-answers/item/malnutrition](https://www.who.int/news-room/questionsand-answers/item/malnutrition) 430
5. WHO Child Growth Standards and the Identification  
431 of Severe Acute Malnutrition in Infants and Children. A  
432 Joint Statement by the World Health Organization and  
433 the United Nations Children's Fund. 2009. [cited 2025  
434 Dec 11]. Available from: [http://www.who.int/nutrition/  
435 publications](http://www.who.int/nutrition/publications) 436
6. International Institute for Population Sciences (IIPS) and  
437 Macro International. National Family Health Survey-3  
438 (NFHS-3). 2007. pp 267–8. 439
7. Analysis of National Family Health Survey 5 (NFHS-5)  
440 Findings. National Family Health Survey-5 (NFHS-5). 2022. 441
8. Management of severe malnutrition: a manual for phy-  
442 sicians and other senior health workers. 1999. [cited  
443 2025 Dec 11]. Available from: [https://www.who.int/  
444 publications/i/item/9241545119](https://www.who.int/publications/i/item/9241545119) 445
9. Hother AL, Girma T, Rytter MJH, Abdissa A, Ritz C, Mølgaard  
446 C, et al. Serum phosphate and magnesium in children  
447 recovering from severe acute undernutrition in Ethiopia:  
448 an observational study. *BMC Pediatrics*. 2016;16(1):178. 449  
450 <https://doi.org/10.1186/s12887-016-0712-9>
10. Cheung J, Johnston R. Refeeding syndrome. *BMJ*.  
451 2004;328(7445):908–9. [https://doi.org/10.1136/  
452 bmj.328.7445.908](https://doi.org/10.1136/bmj.328.7445.908) 453
11. Namusoke H, Hother AL, Rytter MJ, Kästel P, Babirekere-  
454 Iriiso E, Fabiansen C, et al. Changes in plasma phosphate  
455 during in-patient treatment of children with severe acute  
456 malnutrition: an observational study in Uganda. *Am J* 457

- 458 Clin Nutr. 2016;103(2):551–8. <https://doi.org/10.3945/ajcn.115.117374>
- 459
- 460 12. Chanchal R, Gupta S, Kanta C, Singh K, Koonwar S. Hypophosphataemia in severe acute malnutrition: a prospective observational study. *Br J Nutr*. 2019;121(3):306–462 11. <https://doi.org/10.1017/S0007114518003197>
- 463
- 464 13. Yoshimatsu S, Chisti MJ, Hossain MI, Islam MM, Fukushima T, Wagatsuma Y, et al. Hypophosphataemia among severely-malnourished children: case series. *J Health Popul Nutr*. 2012;30(4):491–4.
- 465
- 466
- 467
- 468 14. Dakshayani B, Divyashree P, Sabapathi S, Kariyappa M. Changes in serum phosphorous level during inpatient treatment of children with severe acute malnutrition. *Int J Contemp Pediatrics*. 2019;6(3):1080. <https://doi.org/10.18203/2349-3291>
- 469
- 470
- 471
- 472
- 473 15. Selvaraj A, Sinha R, Singh P, Jain A, Seth A, Kumar P. Serum phosphate profile of children with severe acute malnutrition treated with locally prepared therapeutic feeds: a prospective observational study. *Int J Clin Pediatr*. 2021;10(2-3):35–42. <https://doi.org/10.14740/ijcp458>
- 474
- 475
- 476
- 477
- 478 16. Khan S, Arshad R, Gillani S, Irshad S, Ikram T, Batool N. Serum phosphate level in patients with severe acute malnutrition at Nutrition Stabilization Centre, Children Hospital, and Institute of Child Health Multan. *JIMC*. 2023;18(2):105–8.
- 479
- 480
- 481
- 482
- 483 17. Shukla A, Arya G, Gupta AK, Kumar N, Barman SK. Assessment of clinic-biochemical parameters in severe acute malnutrition children admitted in a tertiary care hospital of Western Uttar Pradesh, India. *Asian J Med Sci*. 2023;14(8):91–7. <https://doi.org/10.3126/ajms.v14i8.53344>
- 484
- 485
- 486
- 487
- 488
- 489 18. Majhi MM, Bhatnagar N. Updated B.G Prasad’s classification for the year 2021: consideration for new base year 2016. *J Fam Med Prim Care*. 2021;10(11):4318–9. [https://doi.org/10.4103/jfmprc.jfmprc\\_987\\_21](https://doi.org/10.4103/jfmprc.jfmprc_987_21)
- 490
- 491
- 492